First-line Anti-GD2 Therapy Combined With Consolidation Chemotherapy in 3 Patients With Newly Diagnosed Metastatic Ewing Sarcoma or Ewing-like Sarcoma

被引:8
作者
Spasov, Neofit J. [1 ]
Dombrowski, Frank [2 ]
Lode, Holger N. [3 ]
Spasova, Mariya [1 ]
Ivanova, Liliya [1 ]
Mumdjiev, Ivan [1 ]
Burnusuzov, Hassan [1 ]
Siebert, Nikolai [3 ]
机构
[1] Med Univ Plovdiv, Dept Pediat & Med Genet, Div Pediat Oncohematol, UMHAT Sveti Georgi 15a,Blvd Vasil Aprilov, Plovdiv 4000, Bulgaria
[2] Univ Med Greifswald, Inst Pathol, Greifswald, Germany
[3] Univ Med Greifswald, Dept Pediat Hematol & Oncol, Greifswald, Germany
关键词
Ewing sarcoma; immunotherapy; anti-GD2; therapy; dinutuximab beta; case report; HIGH-RISK NEUROBLASTOMA; CHILDREN; DINUTUXIMAB; ANTIBODY; CANCER;
D O I
10.1097/MPH.0000000000002488
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Despite multimodal therapy, the prognosis of patients with metastatic Ewing sarcoma (ES) remains poor, with new treatments urgently needed. The disialoganglioside GD2, a well-established tumor-associated antigen, is expressed in 40% to 90% of ES cells, making it a suitable therapeutic target. Here we report 3 cases with newly diagnosed, metastatic, GD2-positive ES or Ewing-like sarcoma treated with the anti-GD2 antibody dinutuximab beta in addition to standard chemotherapeutic regimens. Treatment was well-tolerated, and all patients achieved complete remission, without evidence of relapse. First-line anti-GD2 immunotherapy in patients with metastatic, GD2-positive ES or Ewing-like sarcoma represents a promising therapeutic option that warrants further clinical evaluation.
引用
收藏
页码:E948 / E953
页数:6
相关论文
共 25 条
  • [1] Bailey Kelly, 2019, F1000Res, V8, DOI 10.12688/f1000research.18139.1
  • [2] NCCN Guidelines® Insights Bone Cancer, Version 2.2017 Featured Updates to the NCCN Guidelines
    Biermann, J. Sybil
    Chow, Warren
    Reed, Damon R.
    Lucas, David
    Adkins, Douglas R.
    Agulnik, Mark
    Benjamin, Robert S.
    Brigman, Brian
    Budd, G. Thomas
    Curry, William T.
    Didwania, Aarati
    Fabbri, Nicola
    Hornicek, Francis J.
    Kuechle, Joseph B.
    Lindskog, Dieter
    Mayerson, Joel
    McGarry, Sean V.
    Million, Lynn
    Morris, Carol D.
    Movva, Sujana
    O'Donnell, Richard J.
    Randall, R. Lor
    Rose, Peter
    Santana, Victor M.
    Satcher, Robert L.
    Schwartz, Herbert
    Siegel, Herrick J.
    Thornton, Katherine
    Villalobos, Victor
    Bergman, Mary Anne
    Scavone, Jillian L.
    [J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2017, 15 (02): : 155 - 167
  • [3] Immunotherapy for sarcomas: new frontiers and unveiled opportunities
    Birdi, Harsimrat Kaur
    Jirovec, Anna
    Cortes-Kaplan, Serena
    Werier, Joel
    Nessim, Carolyn
    Diallo, Jean-Simon
    Ardolino, Michele
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (02)
  • [4] Brennan B, 2020, J CLIN ONCOL, V38
  • [5] Exploiting Signaling Pathways and Immune Targets Beyond the Standard of Care for Ewing Sarcoma
    Casey, Dana L.
    Lin, Tsung-Yi
    Cheung, Nai-Kong, V
    [J]. FRONTIERS IN ONCOLOGY, 2019, 9
  • [6] EMA, QARZ DIN BET SUMM PR
  • [7] FDA, DIN PRESCR INF
  • [8] Improved Outcome in Children With Newly Diagnosed High-Risk Neuroblastoma Treated With Chemoimmunotherapy: Updated Results of a Phase II Study Using hu14.18K322A
    Furman, Wayne L.
    McCarville, Beth
    Shulkin, Barry L.
    Davidoff, Andrew
    Krasin, Matthew
    Hsu, Chia-Wei
    Pan, Haitao
    Wu, Jianrong
    Brennan, Rachel
    Bishop, Michael W.
    Helmig, Sara
    Stewart, Elizabeth
    Navid, Fariba
    Triplett, Brandon
    Santana, Victor
    Santiago, Teresa
    Hank, Jacquelyn A.
    Gillies, Stephen D.
    Yu, Alice
    Sondel, Paul M.
    Leung, Wing H.
    Pappo, Alberto
    Federico, Sara M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04) : 335 - +
  • [9] A Phase II Trial of Hu14.18K322A in Combination with Induction Chemotherapy in Children with Newly Diagnosed High-Risk Neuroblastoma
    Furman, Wayne L.
    Federico, Sara M.
    McCarville, Mary Beth
    Shulkin, Barry L.
    Davidoff, Andrew M.
    Krasin, Matthew J.
    Sahr, Natasha
    Sykes, April
    Wu, Jianrong
    Brennan, Rachel C.
    Bishop, Michael William
    Helmig, Sara
    Stewart, Elizabeth
    Navid, Fariba
    Triplett, Brandon
    Santana, Victor M.
    Bahrami, Armita
    Anthony, Gwendolyn
    Yu, Alice L.
    Hank, Jacquelyn
    Gillies, Stephen D.
    Sondel, Paul M.
    Leung, Wing H.
    Pappo, Alberto S.
    [J]. CLINICAL CANCER RESEARCH, 2019, 25 (21) : 6320 - 6328
  • [10] Induction Chemotherapy With an Anti-GD2 Monoclonal Antibody (Dinutuximab) and Cytokines in Children With Newly Diagnosed High-risk Neuroblastoma: A Case Series
    Gartrell, Jessica
    Shulkin, Barry L.
    Helmig, Sara
    Caldwell, Kenneth J.
    Furman, Wayne
    Federico, Sara M.
    [J]. JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2021, 43 (05) : E692 - E696